|Año de nacimiento
|Dr. Giovanni Caforio M.D.
|Executive Chairman of the Board
|Dr. Christopher S. Boerner Ph.D.
|CEO & Director
|Mr. David V. Elkins
|Executive VP & CFO
|Ms. Sandra Leung Esq.
|Executive VP & General Counsel
|Mr. Greg Meyers
|Executive VP and Chief Digital & Technology Officer
|Mr. Timothy Power
|VP & Head of Investor Relations
|Ms. Kimberly M. Jablonski
|Chief Compliance & Ethics Officer
|Ms. Ahn Amanda Poole
|Executive Vice President & Chief Human Resources Officer
|Mr. Samit Hirawat M.D.
|Executive VP & Chief Medical Officer of Drug Development
|Dr. Joseph J. Eiden Jr.
|Head of Medical Affairs
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New York.
La calificación ISS Governance QuickScore de Bristol-Myers Squibb Company a partir del 28 de febrero de 2024 es 2. Las puntuaciones principales son Auditoría: 4; Junta: 5; Derechos del accionista: 2; Compensación: 1.